Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accounts Payables: 2016-2024

Historic Accounts Payables for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $37.8 million.

  • Rocket Pharmaceuticals' Accounts Payables fell 23.90% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year decrease of 23.90%. This contributed to the annual value of $37.8 million for FY2024, which is 17.39% down from last year.
  • As of FY2024, Rocket Pharmaceuticals' Accounts Payables stood at $37.8 million, which was down 17.39% from $45.8 million recorded in FY2023.
  • Rocket Pharmaceuticals' 5-year Accounts Payables high stood at $45.8 million for FY2023, and its period low was $19.6 million during FY2021.
  • Over the past 3 years, Rocket Pharmaceuticals' median Accounts Payables value was $37.8 million (recorded in 2024), while the average stood at $40.1 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Accounts Payables declined by 22.99% in 2021, and later surged by 86.90% in 2022.
  • Rocket Pharmaceuticals' Accounts Payables (Yearly) stood at $25.5 million in 2020, then fell by 22.99% to $19.6 million in 2021, then spiked by 86.90% to $36.7 million in 2022, then rose by 24.90% to $45.8 million in 2023, then dropped by 17.39% to $37.8 million in 2024.